CANDEL THERAPEUTICS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
CANDEL THERAPEUTICS, INC. (CADL) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $2.37 million for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-28.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2024-03-28
- CANDEL THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was $0.00.
- CANDEL THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-09-30 was $0.00.
- CANDEL THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-06-30 was $0.00.
- CANDEL THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-03-31 was $2.37M.
- CANDEL THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $2.37M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $0.00 derived: sum of 2 quarters · filed 2024-03-28 | $0.00 derived: sum of 3 quarters · filed 2024-03-28 | $2.37M 10-K · filed 2024-03-28 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $2.37M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $2.37M 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $2.37M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |